Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

OBJECTIVE—The efficacy and safety of adding liraglutide (a glucagon-like peptide-1 receptor agonist) to metformin were compared with addition of placebo or glimepiride to metformin in subjects previously treated with oral antidiabetes (OAD) therapy. RESEARCH DESIGN AND METHODS—In this 26-week, doubl...

Descripción completa

Detalles Bibliográficos
Autores principales: Nauck, Michael, Frid, Anders, Hermansen, Kjeld, Shah, Nalini S., Tankova, Tsvetalina, Mitha, Ismail H., Zdravkovic, Milan, Düring, Maria, Matthews, David R.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2009
Materias:
Emerging Treatments and Technologies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2606836/
https://www.ncbi.nlm.nih.gov/pubmed/18931095
http://dx.doi.org/10.2337/dc08-1355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2606836/
https://www.ncbi.nlm.nih.gov/pubmed/18931095
http://dx.doi.org/10.2337/dc08-1355

Ejemplares similares